Br J Cancer
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
ABSTRACT
To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted a phase II trial. Eligibility criteria were: chemotherapy-naïve, small-cell lung cancer (SCLC), good performance status (PS: 0-2), age
Related Questions
New answer by Medical Oncologist at University of Michigan Medical School (November 11, 2021)
The patient still has limited-stage, potentially curable disease assuming the PET/CT and MRI brain do not show any other sites of cancer outside of the mediastinum. Treatment ...